Early diagnosis and access to appropriate and timely medications are essential to improving long-term outcomes of patients with NAFLD/NASH. Hilda is herein, providing groundbreaking research discoveries, that would help treat the hepatic complications associated with diabetes without the need to go for liver transplant. 

Hilda’s team have depicted the underlying mechanisms involved in the pathogenesis of NAFLD/NASH, leading to better understanding of the disease, thus the development of a targeted therapy. She aims at establishing an effective-targeted-pharmacological medication against this growing epidemic and improving long-term outcomes of these patients, since there is no FDA approved medication.

She aims at bringing a new drug molecule into clinical practice as such, translating our basic research findings into commercially lunching of the drug. Her future plans encompass clinical trials to translate our finding into clinical settings and assess the efficacy/dose/side effects of the drug. She would be able to lunch an FDA- approved medication specifically developed to curb NAFLD/NASH.